Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
Bhide Y, Dong W, Gribonika I, Voshart D, Meijerhof T, de Vries-Idema J, Norley S, Guilfoyle K, Skeldon S, Engelhardt OG, Boon L, Christensen D, Lycke N, Huckriede A. Bhide Y, et al. Among authors: guilfoyle k. Front Immunol. 2019 Mar 29;10:646. doi: 10.3389/fimmu.2019.00646. eCollection 2019. Front Immunol. 2019. PMID: 30984200 Free PMC article.
Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.
Dong W, Bhide Y, Sicca F, Meijerhof T, Guilfoyle K, Engelhardt OG, Boon L, de Haan CAM, Carnell G, Temperton N, de Vries-Idema J, Kelvin D, Huckriede A. Dong W, et al. Among authors: guilfoyle k. Front Immunol. 2018 Oct 9;9:2312. doi: 10.3389/fimmu.2018.02312. eCollection 2018. Front Immunol. 2018. PMID: 30356772 Free PMC article.
Comparison of single radial immunodiffusion, SDS-PAGE and HPLC potency assays for inactivated influenza vaccines shows differences in ability to predict immunogenicity of haemagglutinin antigen.
Engelhardt OG, Edge C, Dunleavy U, Guilfoyle K, Harvey R, Major D, Newman R, Penn R, Skeldon S, Storey C, Wheeler J, Wood J, Minor P. Engelhardt OG, et al. Among authors: guilfoyle k. Vaccine. 2018 Jul 5;36(29):4339-4345. doi: 10.1016/j.vaccine.2018.05.076. Epub 2018 Jun 9. Vaccine. 2018. PMID: 29895503 Free article.
The development of vaccine viruses against pandemic A(H1N1) influenza.
Robertson JS, Nicolson C, Harvey R, Johnson R, Major D, Guilfoyle K, Roseby S, Newman R, Collin R, Wallis C, Engelhardt OG, Wood JM, Le J, Manojkumar R, Pokorny BA, Silverman J, Devis R, Bucher D, Verity E, Agius C, Camuglia S, Ong C, Rockman S, Curtis A, Schoofs P, Zoueva O, Xie H, Li X, Lin Z, Ye Z, Chen LM, O'Neill E, Balish A, Lipatov AS, Guo Z, Isakova I, Davis CT, Rivailler P, Gustin KM, Belser JA, Maines TR, Tumpey TM, Xu X, Katz JM, Klimov A, Cox NJ, Donis RO. Robertson JS, et al. Among authors: guilfoyle k. Vaccine. 2011 Feb 17;29(9):1836-43. doi: 10.1016/j.vaccine.2010.12.044. Epub 2011 Jan 1. Vaccine. 2011. PMID: 21199698
Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets.
Cox RJ, Major D, Pedersen G, Pathirana RD, Hoschler K, Guilfoyle K, Roseby S, Bredholt G, Assmus J, Breakwell L, Campitelli L, Sjursen H. Cox RJ, et al. Among authors: guilfoyle k. PLoS One. 2015 Jul 6;10(7):e0131652. doi: 10.1371/journal.pone.0131652. eCollection 2015. PLoS One. 2015. PMID: 26147369 Free PMC article. Clinical Trial.
21 results